Clinical Trials
142 trialsLetrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
M.D. Anderson Cancer Center
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
Alliance for Clinical Trials in Oncology
Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer
University of Alabama at Birmingham
CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer
Abramson Cancer Center at Penn Medicine
A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection
St. Joseph's Hospital and Medical Center, Phoenix
SEQTOR
Grupo Espanol de Tumores Neuroendocrinos
RAD001 in Recurrent Endometrial Cancer Patients
M.D. Anderson Cancer Center
RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
M.D. Anderson Cancer Center
Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
M.D. Anderson Cancer Center
Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
M.D. Anderson Cancer Center
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
Thomas Jefferson University
CONTRAC
Dana-Farber Cancer Institute
RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome
Boston Children's Hospital
MIST
Alliance for Clinical Trials in Oncology
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
EVACEL
Federation Francophone de Cancerologie Digestive
Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome
University of Utah
Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast
Avera McKennan Hospital & University Health Center
Everolimus for Children With Recurrent or Progressive Ependymoma
University of Texas Southwestern Medical Center
Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative
M.D. Anderson Cancer Center
DCLNF1
The University of Texas Health Science Center, Houston
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
Rutgers, The State University of New Jersey
Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
Memorial Sloan Kettering Cancer Center
Everolimus With and Without Temozolomide in Adult Low Grade Glioma
University of California, San Francisco
Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium
Memorial Sloan Kettering Cancer Center
Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations
University of Michigan Rogel Cancer Center
Palbociclib With Everolimus + Exemestane In BC
Dana-Farber Cancer Institute
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
Roswell Park Cancer Institute
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Hoosier Cancer Research Network
Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
City of Hope Medical Center
Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer
SCRI Development Innovations, LLC
Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
SCRI Development Innovations, LLC
Phase II Study of Everolimus Beyond Progression
Emory University
Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
University of Maryland, Baltimore
Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
Memorial Sloan Kettering Cancer Center
Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score
Yale University
Study of Everolimus (RAD001) in Combination With Lenalidomide
Emory University
RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM
SCRI Development Innovations, LLC
RAD001 Plus Bevacizumab in Metastatic Melanoma
SCRI Development Innovations, LLC
Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
SCRI Development Innovations, LLC
Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Dana-Farber Cancer Institute
A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD
NYU Langone Health
NECTAR
The Methodist Hospital Research Institute
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
Washington University School of Medicine
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute